News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biopta Stretches Blood Vessel Viability Using Abcellute Cell Preservation Technology


11/15/2007 9:13:24 AM

CARDIFF, Wales--(BUSINESS WIRE)--Early stage studies using human tissue samples are increasingly recognised as key to reducing drug failure rates. Now in a major breakthrough Abcellute’s non-cryogenic cell preservation technology has been successful trialled by Biopta Ltd, a CRO specializing in human tissue in vitro pharmacology. Biopta were able to use Abcellute’s matrix to maintain the viability of fresh blood vessels over 5 days for use on their cardiovascular in vitro testing systems including Biopta’s first instrument, the PM-1, which provides real-time information on the vascular effects of drugs in living tissues.

Read at BioSpace.com

comments powered by Disqus
Biopta
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES